Chronic Cholestatic Liver Injury Attributable to Vedolizumab

Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases res...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational hepatology 2016-09, Vol.4 (3), p.277-280
Main Authors: Stine, Jonathan G, Wang, Jennifer, Behm, Brian W
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-d9451cf94b73f9d20e1f259e84aa24d4d851387c57be3a5d470f7ba048d244883
cites
container_end_page 280
container_issue 3
container_start_page 277
container_title Journal of clinical and translational hepatology
container_volume 4
creator Stine, Jonathan G
Wang, Jennifer
Behm, Brian W
description Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.
doi_str_mv 10.14218/JCTH.2016.00018
format article
fullrecord <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5075012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>lcyzhgbzz_e201603012</wanfj_id><sourcerecordid>lcyzhgbzz_e201603012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-d9451cf94b73f9d20e1f259e84aa24d4d851387c57be3a5d470f7ba048d244883</originalsourceid><addsrcrecordid>eNpVkNFLwzAQxoMobsy9-yT9A-y8pMmSggijqJsMfJm-hqRJt46uHWk7Wf9621WH3ssd3Pd9d_wQusUwwZRg8fAWreYTAng6AQAsLtCQBBh8IXB42c6EMB84DgdoXJbbTsIwTEO4RgPC2xIhH6LHaOOKPI29aFNktqxU1c7L9GCdt8i3tTt6s6pyqa4rpTPrVYX3aU2RpU29U_oGXSUqK-34p4_Qx8vzKpr7y_fXRTRb-jEFqHwTUobjJKSaB0loCFicEBZaQZUi1FAjGA4EjxnXNlDMUA4J1wqoMIRSIYIReupz97XeWRPbvHIqk3uX7pQ7ykKl8v8mTzdyXRwkA84Akzbgvg_4Unmi8rXcFrXL25dlFh-bzVo3jbQdSQh6OfTy2BVl6WxyPoVBntjLjr3sHPLEvrXc_X3xbPglHXwDtSB_6w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic Cholestatic Liver Injury Attributable to Vedolizumab</title><source>PubMed Central Free</source><creator>Stine, Jonathan G ; Wang, Jennifer ; Behm, Brian W</creator><creatorcontrib>Stine, Jonathan G ; Wang, Jennifer ; Behm, Brian W</creatorcontrib><description>Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.</description><identifier>ISSN: 2225-0719</identifier><identifier>EISSN: 2310-8819</identifier><identifier>DOI: 10.14218/JCTH.2016.00018</identifier><identifier>PMID: 27777897</identifier><language>eng</language><publisher>China: Division of Gastroenterology &amp; Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA%Department of Medicine, University of Virginia, Charlottesville, VA, USA</publisher><subject>Case Report</subject><ispartof>Journal of clinical and translational hepatology, 2016-09, Vol.4 (3), p.277-280</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2016 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA &amp; HE Publishing Inc. All rights reserved. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-d9451cf94b73f9d20e1f259e84aa24d4d851387c57be3a5d470f7ba048d244883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/lcyzhgbzz-e/lcyzhgbzz-e.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075012/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075012/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27777897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stine, Jonathan G</creatorcontrib><creatorcontrib>Wang, Jennifer</creatorcontrib><creatorcontrib>Behm, Brian W</creatorcontrib><title>Chronic Cholestatic Liver Injury Attributable to Vedolizumab</title><title>Journal of clinical and translational hepatology</title><addtitle>J Clin Transl Hepatol</addtitle><description>Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.</description><subject>Case Report</subject><issn>2225-0719</issn><issn>2310-8819</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkNFLwzAQxoMobsy9-yT9A-y8pMmSggijqJsMfJm-hqRJt46uHWk7Wf9621WH3ssd3Pd9d_wQusUwwZRg8fAWreYTAng6AQAsLtCQBBh8IXB42c6EMB84DgdoXJbbTsIwTEO4RgPC2xIhH6LHaOOKPI29aFNktqxU1c7L9GCdt8i3tTt6s6pyqa4rpTPrVYX3aU2RpU29U_oGXSUqK-34p4_Qx8vzKpr7y_fXRTRb-jEFqHwTUobjJKSaB0loCFicEBZaQZUi1FAjGA4EjxnXNlDMUA4J1wqoMIRSIYIReupz97XeWRPbvHIqk3uX7pQ7ykKl8v8mTzdyXRwkA84Akzbgvg_4Unmi8rXcFrXL25dlFh-bzVo3jbQdSQh6OfTy2BVl6WxyPoVBntjLjr3sHPLEvrXc_X3xbPglHXwDtSB_6w</recordid><startdate>20160928</startdate><enddate>20160928</enddate><creator>Stine, Jonathan G</creator><creator>Wang, Jennifer</creator><creator>Behm, Brian W</creator><general>Division of Gastroenterology &amp; Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA%Department of Medicine, University of Virginia, Charlottesville, VA, USA</general><general>XIA &amp; HE Publishing Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20160928</creationdate><title>Chronic Cholestatic Liver Injury Attributable to Vedolizumab</title><author>Stine, Jonathan G ; Wang, Jennifer ; Behm, Brian W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-d9451cf94b73f9d20e1f259e84aa24d4d851387c57be3a5d470f7ba048d244883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Case Report</topic><toplevel>online_resources</toplevel><creatorcontrib>Stine, Jonathan G</creatorcontrib><creatorcontrib>Wang, Jennifer</creatorcontrib><creatorcontrib>Behm, Brian W</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical and translational hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stine, Jonathan G</au><au>Wang, Jennifer</au><au>Behm, Brian W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Cholestatic Liver Injury Attributable to Vedolizumab</atitle><jtitle>Journal of clinical and translational hepatology</jtitle><addtitle>J Clin Transl Hepatol</addtitle><date>2016-09-28</date><risdate>2016</risdate><volume>4</volume><issue>3</issue><spage>277</spage><epage>280</epage><pages>277-280</pages><issn>2225-0719</issn><eissn>2310-8819</eissn><abstract>Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.</abstract><cop>China</cop><pub>Division of Gastroenterology &amp; Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA%Department of Medicine, University of Virginia, Charlottesville, VA, USA</pub><pmid>27777897</pmid><doi>10.14218/JCTH.2016.00018</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2225-0719
ispartof Journal of clinical and translational hepatology, 2016-09, Vol.4 (3), p.277-280
issn 2225-0719
2310-8819
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5075012
source PubMed Central Free
subjects Case Report
title Chronic Cholestatic Liver Injury Attributable to Vedolizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A46%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Cholestatic%20Liver%20Injury%20Attributable%20to%20Vedolizumab&rft.jtitle=Journal%20of%20clinical%20and%20translational%20hepatology&rft.au=Stine,%20Jonathan%20G&rft.date=2016-09-28&rft.volume=4&rft.issue=3&rft.spage=277&rft.epage=280&rft.pages=277-280&rft.issn=2225-0719&rft.eissn=2310-8819&rft_id=info:doi/10.14218/JCTH.2016.00018&rft_dat=%3Cwanfang_jour_pubme%3Elcyzhgbzz_e201603012%3C/wanfang_jour_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-d9451cf94b73f9d20e1f259e84aa24d4d851387c57be3a5d470f7ba048d244883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/27777897&rft_wanfj_id=lcyzhgbzz_e201603012&rfr_iscdi=true